CNTGF (Centogene NV) Debt-to-Asset : 1.04 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Debt-to-Asset?

Centogene NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $30.60 Mil. Centogene NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $57.01 Mil. Centogene NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $84.14 Mil. Centogene NV's debt to asset for the quarter that ended in Dec. 2023 was 1.04.

Centogene NV Debt-to-Asset Historical Data

The historical data trend for Centogene NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Debt-to-Asset Chart

Centogene NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.23

0.16

0.25

0.65

1.04

Centogene NV Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.40	0.46	0.65	0.83	1.04

Competitive Comparison of Centogene NV's Debt-to-Asset

For the Diagnostics & Research subindustry, Centogene NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centogene NV's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Centogene NV's Debt-to-Asset falls into.

Centogene NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Centogene NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(30.6	+	57.011)	/	84.138
	=	1.04

Centogene NV's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(30.6	+	57.011)	/	84.138
	=	1.04

Centogene NV (OTCPK:CNTGF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Centogene NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Centogene NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Centogene NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (OTCPK:CNTGF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

39K:Germany

Address

Am Strande 7, Rostock, MV, DEU, 18055

Website

https://www.centogene.com

Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.